DREADD: A Chemogenetic GPCR Signaling Platform

Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hu, Roth, Bryan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Trends and Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368861/
https://www.ncbi.nlm.nih.gov/pubmed/25522378
http://dx.doi.org/10.1093/ijnp/pyu007
_version_ 1782362703467118592
author Zhu, Hu
Roth, Bryan L.
author_facet Zhu, Hu
Roth, Bryan L.
author_sort Zhu, Hu
collection PubMed
description Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering.
format Online
Article
Text
id pubmed-4368861
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43688612015-09-01 DREADD: A Chemogenetic GPCR Signaling Platform Zhu, Hu Roth, Bryan L. Int J Neuropsychopharmacol Trends and Perspectives Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering. Oxford University Press 2014-12-19 /pmc/articles/PMC4368861/ /pubmed/25522378 http://dx.doi.org/10.1093/ijnp/pyu007 Text en © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Trends and Perspectives
Zhu, Hu
Roth, Bryan L.
DREADD: A Chemogenetic GPCR Signaling Platform
title DREADD: A Chemogenetic GPCR Signaling Platform
title_full DREADD: A Chemogenetic GPCR Signaling Platform
title_fullStr DREADD: A Chemogenetic GPCR Signaling Platform
title_full_unstemmed DREADD: A Chemogenetic GPCR Signaling Platform
title_short DREADD: A Chemogenetic GPCR Signaling Platform
title_sort dreadd: a chemogenetic gpcr signaling platform
topic Trends and Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368861/
https://www.ncbi.nlm.nih.gov/pubmed/25522378
http://dx.doi.org/10.1093/ijnp/pyu007
work_keys_str_mv AT zhuhu dreaddachemogeneticgpcrsignalingplatform
AT rothbryanl dreaddachemogeneticgpcrsignalingplatform

Ejemplares similares